Incyte vs Iqvia
INCY and IQV side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INCY and IQV compare
Iqvia is the larger company, worth 1.8 times as much as Incyte ($44.0B against $24.4B).
On earnings, Iqvia is cheaper: it trades at 33.2× trailing earnings, against 64.0× for Incyte.
Incyte grew revenue faster over the last twelve months (24.9% versus 8.2% for Iqvia).
Iqvia keeps more of each dollar of sales as profit, with a net margin of 8.1% compared with 6.7% at Incyte.
Incyte scores higher on the StockData Score (13 against 8 for Iqvia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INCY | IQV |
|---|---|---|
| Size and price | ||
| Market cap | $24.4B | $44.0B |
| Share price | $120.39 | $267.33 |
| Change, 1 year | 33.5% | 22.7% |
| Change, 5 years | 77.4% | 8.1% |
| Beta (5Y) | 0.45 | 1.17 |
| Employees | 2,844 | 93K |
| StockData Score | ||
| Total score | 13 (better) | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 6 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 64.0× | 33.2× (better) |
| P/S | 4.1× | 2.6× (better) |
| P/B | 4.3× (better) | 7.1× |
| EV/EBITDA | 29.1× | 17.2× (better) |
| P/FCF | – | 20.1× |
| PEG | 1.04 (better) | 2.99 |
| FCF yield | – | 5.0% |
| Fair value | $66.29 | $222.72 |
| Margin of safety | −81.6% | −20.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 24.9% (better) | 8.2% |
| Revenue growth, 5Y average | 14.0% (better) | 7.5% |
| Net income growth (TTM) | −66.1% | 11.2% (better) |
| EPS growth (TTM) | −68.2% | 16.6% (better) |
| EPS growth, 5Y average | – | 40.5% |
| Profitability | ||
| Gross margin | 92.7% (better) | 33.0% |
| Operating margin | 10.4% | 13.0% (better) |
| Net margin | 6.7% | 8.1% (better) |
| FCF margin | – | 12.9% |
| Return on equity | 7.8% | 23.0% (better) |
| Return on invested capital | 13.9% (better) | 9.4% |
| Financial health | ||
| Debt / equity | 0.00 | 2.59 (better) |
| Net debt / EBITDA | – | 4.11 |
| Interest coverage | 268× (better) | 2.9× |
| Current ratio | 3.84 (better) | 0.71 |
| Altman Z-score | 10.75 (better) | 2.20 |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 2.6% |
| Shareholder yield | 0.00% | 2.6% (better) |
| Ownership | ||
| Held by institutions | 100.0% | 95.3% |
| Held by insiders | 33.4% | 1.1% |
| Insider net buying, 12 months | −$58.0M | −$38.0M (better) |
| Superinvestors holding | – | 3 |
| Short interest, % of float | 7.4% | 2.0% |
Go deeper
- INCY stock overview
- INCY income statement
- INCY valuation and score
- IQV stock overview
- IQV income statement
- IQV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.